This site is intended for healthcare professionals
CDK4/6 inhibitor selection in metastatic breast cancer

Publication digest

Read time: 15 mins
Last updated:16th Dec 2020
Published:16th Dec 2020

CDK4/6 inhibitors in combination with endocrine therapy as potential therapies for treating high-risk early breast cancer patients

Does addition of abemaciclib to endocrine therapy (ET) as an adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer patients provide additional benefits versus treatment with ET alone?

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest